Moderna-Merck Cancer Vaccine Crushes Late-Stage Trial Results
A Moderna-Merck melanoma vaccine combo beat Keytruda alone in a late-stage trial, sending both stocks surging.
If you're watching biotech, drop everything. Moderna and Merck just dropped a blockbuster readout from a late-stage clinical trial of their experimental cancer vaccine combo — and the market is responding exactly how you'd expect.
The combination regimen, pairing Moderna's personalized mRNA vaccine with Merck's blockbuster immunotherapy Keytruda, significantly extended the time melanoma patients went without their cancer coming back. That's the key metric in oncology trials — progression-free survival — and beating it in a late-stage study is no small feat. This wasn't a Phase 1 safety check. This is the real deal.
Read more Gulf Stock Markets Climb as Oil Price Gains Boost Mood →
Both stocks soared on the news. That kind of dual pop tells you the Street sees this as a genuine shared win, not a situation where one partner carries the other. Moderna needs this badly — its post-pandemic revenue story has been under pressure, and a validated cancer franchise would completely reframe the bull case. For Merck, it deepens the moat around Keytruda, which already dominates cancer treatment but faces patent headwinds down the road.
The bigger picture here is what this means for mRNA technology beyond COVID. Moderna has argued for years that the platform is a pipeline, not a product. A successful cancer vaccine would be the strongest proof yet that the bet was right. If this combo eventually reaches patients at scale, you're looking at one of the more significant oncology approvals in recent memory — and two stocks that the market may still be underpricing given the size of the melanoma and broader skin cancer market.
Stay locked in as regulatory next steps come into focus. Continue reading at US Top News and Analysis.
